Nifty
Sensex
:
:
12010.20
40342.67
113.40 (0.95%)
-201.70 (-0.50%)

Chemicals

Rating :
63/99  (View)

BSE: 530019 | NSE: JUBILANT

700.25
5.85 (0.84%)
21-Oct-2020 | 2:04PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  705.00
  •  718.90
  •  697.35
  •  694.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  192706
  •  1349.42
  •  909.00
  •  234.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,053.31
  • 13.79
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,281.66
  • 0.72%
  • 1.94

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.68%
  • 3.69%
  • 14.57%
  • FII
  • DII
  • Others
  • 26.96%
  • 1.18%
  • 2.92%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.26
  • 9.75
  • 6.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.17
  • 9.32
  • 5.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.61
  • 18.05
  • 11.80

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.87
  • 15.78
  • 14.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.91
  • 2.44
  • 2.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.33
  • 8.92
  • 8.26

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
1,893
2,182
-13%
2,391
2,386
0%
2,315
2,377
-3%
2,266
2,269
0%
Expenses
1,591
1,747
-9%
1,855
2,028
-9%
1,808
1,884
-4%
1,797
1,819
-1%
EBITDA
302
435
-30%
537
358
50%
507
493
3%
468
450
4%
EBIDTM
16%
20%
14%
15%
22%
21%
21%
20%
Other Income
8
10
-16%
19
-7
-
6
29
-79%
12
4
220%
Interest
76
73
5%
71
62
16%
72
53
36%
72
54
32%
Depreciation
112
103
9%
129
95
36%
113
98
15%
117
89
31%
PBT
122
269
-55%
356
-40
-
293
356
-18%
292
302
-3%
Tax
34
84
-59%
95
61
57%
90
88
2%
43
92
-53%
PAT
88
185
-52%
260
-101
-
203
268
-24%
249
210
19%
PATM
5%
8%
7%
-4%
9%
11%
11%
9%
EPS
5.52
11.61
-52%
16.35
-6.32
-
12.77
16.79
-24%
15.66
13.17
19%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
8,865
9,154
9,111
7,518
5,861
5,749
5,826
5,803
5,166
4,303
3,446
Net Sales Growth
-4%
0%
21%
28%
2%
-1%
0%
12%
20%
25%
 
Cost Of Goods Sold
6,810
3,141
3,522
2,863
2,003
2,116
2,663
2,438
2,063
1,619
1,340
Gross Profit
2,055
6,014
5,589
4,655
3,859
3,633
3,163
3,365
3,103
2,684
2,106
GP Margin
23%
66%
61%
62%
66%
63%
54%
58%
60%
62%
61%
Total Expenditure
7,051
7,207
7,372
5,999
4,516
4,502
5,125
4,782
4,098
3,413
2,881
Power & Fuel Cost
-
474
466
425
334
367
393
390
357
287
224
% Of Sales
-
5%
5%
6%
6%
6%
7%
7%
7%
7%
6%
Employee Cost
-
2,128
1,926
1,556
1,231
1,125
1,090
1,105
963
836
719
% Of Sales
-
23%
21%
21%
21%
20%
19%
19%
19%
19%
21%
Manufacturing Exp.
-
603
552
486
429
436
432
405
360
330
285
% Of Sales
-
7%
6%
6%
7%
8%
7%
7%
7%
8%
8%
General & Admin Exp.
-
488
541
355
281
256
302
264
208
201
196
% Of Sales
-
5%
6%
5%
5%
4%
5%
5%
4%
5%
6%
Selling & Distn. Exp.
-
293
268
248
186
136
204
160
123
112
91
% Of Sales
-
3%
3%
3%
3%
2%
4%
3%
2%
3%
3%
Miscellaneous Exp.
-
82
97
68
53
66
40
20
24
28
91
% Of Sales
-
1%
1%
1%
1%
1%
1%
0%
0%
1%
1%
EBITDA
1,815
1,947
1,739
1,518
1,345
1,247
702
1,021
1,068
890
565
EBITDA Margin
20%
21%
19%
20%
23%
22%
12%
18%
21%
21%
16%
Other Income
46
47
36
40
25
13
42
19
30
31
17
Interest
291
287
220
284
341
371
368
337
311
238
120
Depreciation
472
462
371
415
291
347
288
281
254
221
180
PBT
1,064
1,245
1,184
859
738
542
88
422
533
463
282
Tax
262
312
327
225
163
155
80
70
152
68
13
Tax Rate
25%
26%
36%
26%
22%
29%
200%
34%
45%
60%
6%
PAT
801
898
574
643
576
392
-58
109
153
15
230
PAT before Minority Interest
801
898
577
634
575
387
-40
138
189
46
227
Minority Interest
0
0
-3
8
1
5
-18
-29
-36
-31
2
PAT Margin
9%
10%
6%
9%
10%
7%
-1%
2%
3%
0%
7%
PAT Growth
43%
56%
-11%
12%
47%
778%
-153%
-29%
949%
-94%
 
EPS
50.30
56.39
36.06
40.35
36.14
24.60
-3.63
6.84
9.59
0.91
14.42

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
5,604
4,809
4,087
3,436
2,966
2,454
2,627
2,476
2,257
2,172
Share Capital
16
16
16
16
16
16
15
16
16
16
Total Reserves
5,588
4,793
4,071
3,420
2,951
2,438
2,611
2,460
2,241
2,156
Non-Current Liabilities
4,088
4,420
3,417
3,826
3,347
4,036
2,185
3,005
3,224
3,048
Secured Loans
729
812
730
1,582
2,620
3,316
1,717
1,709
2,839
2,436
Unsecured Loans
3,011
3,431
2,318
1,923
393
375
0
760
0
401
Long Term Provisions
151
114
107
81
70
67
220
238
170
40
Current Liabilities
2,619
2,090
2,005
1,684
2,464
2,129
3,894
2,778
2,213
2,270
Trade Payables
1,090
1,020
1,136
749
612
721
718
647
837
517
Other Current Liabilities
674
474
506
573
951
793
1,731
898
500
466
Short Term Borrowings
650
500
245
256
749
517
1,188
1,131
767
883
Short Term Provisions
205
96
118
106
152
97
257
102
109
403
Total Liabilities
12,310
11,319
9,457
8,899
8,740
8,619
8,864
8,371
7,763
7,532
Net Block
6,340
5,648
5,401
5,107
5,104
4,911
5,099
4,967
4,460
3,991
Gross Block
7,983
6,906
6,289
5,672
5,391
7,362
7,331
6,870
6,084
5,163
Accumulated Depreciation
1,643
1,257
888
566
286
2,451
2,232
1,903
1,624
1,172
Non Current Assets
7,272
6,734
6,267
5,951
5,864
5,904
5,936
5,810
5,466
4,940
Capital Work in Progress
768
901
671
684
611
597
472
437
686
667
Non Current Investment
69
115
124
103
85
40
34
26
19
33
Long Term Loans & Adv.
87
69
72
56
63
327
328
379
300
249
Other Non Current Assets
8
1
1
1
1
30
2
0
1
1
Current Assets
5,038
4,585
3,190
2,948
2,875
2,715
2,928
2,561
2,297
2,592
Current Investments
0
0
0
0
0
0
0
0
0
0
Inventories
1,845
1,417
1,391
1,220
1,203
1,235
1,341
1,116
1,020
691
Sundry Debtors
1,293
1,272
1,131
1,005
950
819
806
709
653
520
Cash & Bank
1,400
1,370
249
460
345
394
480
356
267
1,045
Other Current Assets
500
486
373
226
377
266
301
380
358
335
Short Term Loans & Adv.
41
40
46
37
133
145
136
182
257
218
Net Current Assets
2,419
2,495
1,185
1,264
411
585
-966
-217
85
322
Total Assets
12,310
11,319
9,457
8,899
8,740
8,619
8,864
8,371
7,763
7,532

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,543
1,122
1,303
1,268
1,099
783
772
970
707
390
PBT
1,211
904
859
738
542
40
207
341
114
241
Adjustment
761
862
688
638
738
726
757
752
795
318
Changes in Working Capital
-180
-301
14
37
-133
96
-111
-4
-137
-84
Cash after chg. in Working capital
1,792
1,465
1,561
1,412
1,147
863
853
1,089
773
475
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-249
-343
-258
-144
-48
-79
-81
-120
-65
-85
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-327
-1,012
-618
-450
-313
-343
-174
-500
-594
-352
Net Fixed Assets
-242
-306
-148
-115
786
1,162
-167
-286
-434
-275
Net Investments
0
-58
3
0
57
240
-28
-19
-96
5
Others
-85
-649
-473
-335
-1,155
-1,746
20
-195
-64
-82
Cash from Financing Activity
-1,050
657
-901
-686
-843
-503
-414
-450
-889
608
Net Cash Inflow / Outflow
166
767
-216
132
-56
-63
183
20
-776
646
Opening Cash & Equivalents
1,005
244
456
339
392
473
280
263
1,041
498
Closing Cash & Equivalent
1,231
1,005
244
456
339
392
473
280
263
1,041

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
352
302
262
221
191
154
170
155
142
136
ROA
8%
6%
7%
7%
4%
0%
2%
2%
1%
3%
ROE
17%
13%
17%
18%
14%
-2%
5%
8%
2%
10%
ROCE
15%
13%
15%
14%
12%
6%
8%
10%
6%
6%
Fixed Asset Turnover
1.23
1.38
1.26
1.09
0.92
0.81
0.84
0.82
0.78
0.70
Receivable days
51
48
52
59
55
50
47
47
49
54
Inventory Days
65
56
63
74
76
79
76
74
71
72
Payable days
53
55
57
55
53
52
51
45
39
51
Cash Conversion Cycle
63
49
58
78
77
76
71
75
81
74
Total Debt/Equity
0.83
1.01
0.85
1.18
1.51
1.95
1.67
1.71
1.69
1.81
Interest Cover
5
5
4
3
2
1
2
2
1
3

News Update


  • Jubilant Life Sciences raises Rs 90 crore via Commercial Papers
    12th Oct 2020, 15:47 PM

    Date of maturity of the said commercial papers is November 26, 2020

    Read More
  • Jubilant Life Sciences focusing on sustaining operational, financial performance in near-term
    24th Aug 2020, 13:14 PM

    The company posted a total revenue from operations of Rs 9,154.4 crore in FY20

    Read More
  • Jubilant Life Sciences presents 1,000 vials of Remdesivir to UP CM
    10th Aug 2020, 15:16 PM

    The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company’s distribution network

    Read More
  • Jubilant Life Sciences’ arm launches remdesivir for COVID-19 treatment in India
    4th Aug 2020, 08:53 AM

    The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network.

    Read More
  • Jubilant Life Sciences’ arm gets DCGI’s nod to manufacture remdesivir for treatment of COVID-19
    21st Jul 2020, 08:45 AM

    The company will distribute the drug in the Indian market through its distribution network and will be available by the first week of August 2020

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.